Date: 14-Aug-2020

Pfizer BioNTech Vaccine Induces Immune Response In Early Phase Trial

A Covid-19 vaccine candidate co-developed by the pharmaceutical giant Pfizer and the German biotech firm BioNTech induces a “robust” immune response in healthy adults aged 18–55 years, according to an interim report of an early phase clinical trial, published in Nature on Wednesday. Researchers noted that BNT162b1 is an RNA vaccine that elicits an immune response by mimicking the mRNA molecule used by the novel coronavirus Sars-CoV-2 to build its infectious proteins. According to the study the vaccine candidate is delivered intramuscularly, and enables human cells to produce proteins part of the SARS-CoV-2 receptor-binding domain, against which the immune system is trained to produce antibodies. In the ongoing trial, the scientists assessed the safety, side effects, and safe dose of the vaccine candidate in 45 healthy adults. agencies